The Latin America, Middle East and Africa Contrast Media Market is expected to witness market growth of 4.55% CAGR during the forecast period (2019-2025).
Development of the contrast media market in Middle Eastern and Latin American countries is influenced by the growing inclination towards picture guided diagnostics and strategies. Another key trend noticed is the rising mortality of interminable ailments like gastrointestinal disarranges and cardiovascular diseases. That being said, there are various adverse effects of contrast media on the body and also, they come with infeasible costs. These factors impeded market growth in this region to some extent.
The contrast media of gadolinium consists of complex molecules, arrangements of atoms bound together by chemical bonds. A gadolinium ion and a carrier molecule (a chelating agent) form the chemical bonds. A chelating agent prevents gadolinium from being toxic while preserving its contrasting properties. Different contrast medium brands of gadolinium use specific chelating molecules. The contrast medium is injected intravenously (into a vein) as part of an MRI scan and removed from the body through the kidneys.
Ultrasound segment growth can be largely attributed to several benefits offered by ultrasound contrast agents over other contrast agents and the increasing number of approvals for ultrasound contrast agents in the US, Europe, and Japan. Cardiovascular MRI is primarily being used to test cardiac masses, ischemic heart disease, complex congenital heart disease, and vascular anatomy all through the body. Several diversified contrast media can be used to improve the sensitivity and specificity of detecting and assessing various pathologies, and knowledge of these agents' different mechanisms of action, distribution and protection profiles is needed for safe and effective imaging.
Based on Product Type, the market is segmented into Iodinated, Barium-based, Gadolinium-based and Microbubble. Based on Application, the market is segmented into Neurological disorders, Cancer, Cardiovascular disorders, Gastrointestinal disorders, Nephrological disorders, Musculoskeletal disorders and Other Applications. Based on Modality, the market is segmented into X-ray/CT, MRI and Ultrasound. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segmentation:
By Product Type
By Application
By Modality
By Country
Companies Profiled
Unique Offerings from the Publisher
Development of the contrast media market in Middle Eastern and Latin American countries is influenced by the growing inclination towards picture guided diagnostics and strategies. Another key trend noticed is the rising mortality of interminable ailments like gastrointestinal disarranges and cardiovascular diseases. That being said, there are various adverse effects of contrast media on the body and also, they come with infeasible costs. These factors impeded market growth in this region to some extent.
The contrast media of gadolinium consists of complex molecules, arrangements of atoms bound together by chemical bonds. A gadolinium ion and a carrier molecule (a chelating agent) form the chemical bonds. A chelating agent prevents gadolinium from being toxic while preserving its contrasting properties. Different contrast medium brands of gadolinium use specific chelating molecules. The contrast medium is injected intravenously (into a vein) as part of an MRI scan and removed from the body through the kidneys.
Ultrasound segment growth can be largely attributed to several benefits offered by ultrasound contrast agents over other contrast agents and the increasing number of approvals for ultrasound contrast agents in the US, Europe, and Japan. Cardiovascular MRI is primarily being used to test cardiac masses, ischemic heart disease, complex congenital heart disease, and vascular anatomy all through the body. Several diversified contrast media can be used to improve the sensitivity and specificity of detecting and assessing various pathologies, and knowledge of these agents' different mechanisms of action, distribution and protection profiles is needed for safe and effective imaging.
Based on Product Type, the market is segmented into Iodinated, Barium-based, Gadolinium-based and Microbubble. Based on Application, the market is segmented into Neurological disorders, Cancer, Cardiovascular disorders, Gastrointestinal disorders, Nephrological disorders, Musculoskeletal disorders and Other Applications. Based on Modality, the market is segmented into X-ray/CT, MRI and Ultrasound. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segmentation:
By Product Type
- Iodinated
- Barium-based
- Gadolinium-based
- Microbubble
By Application
- Neurological disorders
- Cancer
- Cardiovascular disorders
- Gastrointestinal disorders
- Nephrological disorders
- Musculoskeletal disorders
- Other Applications
By Modality
- X-ray/CT
- MRI
- Ultrasound
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Bayer AG
- General Electric (GE) Co. (GE Healthcare)
- The Guerbet Group
- Lantheus Holdings, Inc.
- Bracco S.p.A.
- Trivitron Healthcare Pvt. Ltd.
- Nano Therapeutics Pvt. Ltd.
- Magnus Health, LLC (Veracross LLC)
- Imax Diagnostic Imaging Limited
- Daiichi Sankyo Company, Limited
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Contrast Media Market by Product Type
Chapter 5. LAMEA Contrast Media Market by Application
Chapter 6. LAMEA Contrast Media Market by Modality
Chapter 7. LAMEA Contrast Media Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bayer AG
- General Electric (GE) Co. (GE Healthcare)
- The Guerbet Group
- Lantheus Holdings, Inc.
- Bracco S.p.A.
- Trivitron Healthcare Pvt. Ltd.
- Nano Therapeutics Pvt. Ltd.
- Magnus Health, LLC (Veracross LLC)
- Imax Diagnostic Imaging Limited
- Daiichi Sankyo Company, Limited
Methodology
LOADING...
